Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. First-in Human Clinical Transplant Trial for Severe Aplastic Anemia

    ... cells that underwent ex-vivo T cell depletion. This trial started in 2009 and was the first of its kind for aplastic anemia. It’s ... Position / Title:  Clinical Director Institution:  ...

    Interview last updated 10/04/2017 - 1:36pm.

  2. How we treat higher-risk myelodysplastic syndromes

    ... is less than 6 months, and consideration should be given to clinical trials. Higher-risk eligible patients should be offered consultation ... therapy, induction chemotherapy or a clinical trial should be considered to prevent disease progression, although the ...

    Research Article last updated 01/08/2014 - 8:57am.

  3. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and AML with del(5q). Early-phase trials in HR-MDS ... In this article, we review the results of a Phase I trial of a sequential azacitidine-lenalidomide combination approach in patients ...

    Research Article last updated 06/28/2013 - 1:24pm.

  4. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia

    ... peripheral-blood lymphocytes and is preferred in other clinical circumstances. METHODS: From December 2005 through July 2010, we performed a randomized trial comparing these two ATG formulations in conventional regimens. Patients ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... and the malignant clone . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging ... addition of lenalidomide to azacitidine provides additional clinical benefit over azacitidine monotherapy. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. An update on the treatment of myelodysplastic syndromes.

    ... , are approved for intermediate-2- and high-risk MDS. Trial results have increased the understanding of these treatments, alone or ... often requires at least three to six months to achieve a clinical response. In the meantime, or in addition to active therapy, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... BACKGROUND: In the AZA-001 trial, azacitidine (75 mg/m(2)/d subcutaneously for Days 1-7 of every ... category in 48% of patients, and therefore may enhance clinical benefit in patients with higher-risk MDS. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

    ... Decitabine given on a 5-day schedule provided meaningful clinical benefit for patients with MDS, with more than half demonstrating ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Finding a Trial

    ... Finding a Clinical Trial If you are considering joining a clinical trial, the first step is ...

    Page last updated 01/20/2015 - 4:59pm.

  10. Finding a Trial

    ... Finding a Clinical Trial If you are considering joining a clinical trial, the first step is ...

    Page last updated 01/20/2015 - 4:47pm.